SCHEMBL4778622

SCHEMBL4778622

N#Cc1ccc(COC2COc3nc([N+](=O)[O-])cn3C2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 1/20 0.69
DRD4 P21917 1/20 0.37
TMEM97 Q5BJF2 1/20 0.37
SIGMAR1 Q99720 1/20 0.37
CYP19A1 P11511 1/20 0.36
KCNH2 Q12809 6/20 0.35
KCNJ1 P48048 1/20 0.35
JAK2 O60674 2/20 0.35
MAPT P10636 2/20 0.34
ALDH1A1 P00352 1/20 0.34
ABCB1 P08183 1/20 0.34
GAA P10253 1/20 0.34
ABCG2 Q9UNQ0 1/20 0.34
JAK3 P52333 1/20 0.34
SLC6A2 P23975 1/20 0.34
SLC6A4 P31645 1/20 0.34
SLC6A3 Q01959 1/20 0.34
CYP11B2 P19099 1/20 0.33
NAAA Q02083 2/20 0.32
CTSL P07711 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL509323 0.90 CHRM1 (0.69) CHRM1KCNH2JAK2ALDH1A1SLC6A2
SCHEMBL3187069 0.86 CHRM1 (0.73) CHRM1KCNH2SLC6A2SLC6A4
SCHEMBL3187077 0.86 CHRM1 (0.73) CHRM1KCNH2SLC6A2SLC6A4
SCHEMBL508705 0.86 CHRM1 (0.73) CHRM1KCNH2SLC6A2SLC6A4
SCHEMBL509156 0.86 CHRM1 (0.73) CHRM1DRD4SIGMAR1KCNH2MAPT
SCHEMBL3194998 0.86 CHRM1 (0.73) CHRM1DRD4SIGMAR1KCNH2MAPT
SCHEMBL14004011 0.86 CHRM1 (0.73) CHRM1SIGMAR1CYP19A1KCNH2ALDH1A1
SCHEMBL29808816 0.86 CHRM1 (0.73) CHRM1SIGMAR1CYP19A1KCNH2ALDH1A1
SCHEMBL13198620 0.84 CHRM1 (0.79) CHRM1KCNH2SLC6A2SLC6A4NAAA
SCHEMBL4840823 0.84 CHRM1 (0.69) CHRM1TMEM97KCNH2MAPTPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080275035-A1 Nitroimidazole Compounds JIRICEK JAN 2008-11-06 US disclosed
US-20080275035-A1 Nitroimidazole Compounds JIRICEK JAN 2008-11-06 US disclosed
US-20080275035-A1 Nitroimidazole Compounds JIRICEK JAN 2008-11-06 US disclosed
EP-1984369-A2 NITROIMIDAZOLE COMPOUNDS Novartis AG (CH) 2008-10-29 EP disclosed
WO-2007075872-A2 NITROIMIDAZOLE COMPOUNDS NOVARTIS AG (CH) 2007-07-05 WO disclosed
WO-2007075872-A2 NITROIMIDAZOLE COMPOUNDS NOVARTIS AG (CH) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275035-A1 Nitroimidazole Compounds NQO2, NQO1, MT-ND2 CHRM1 1746/4885DRD4 1436/4885TMEM97 1310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.